Heron Therapeutics (HRTX) Misses Q2 EPS by 2c, provides guidance

Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $36.02 million versus the consensus estimate of $36.09 million.

Guidance:

Adjusted Operating Expenses: $107.0 to $111.0 million
Adjusted EBITDA: $(10.0) to $3.0 million

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• BuzzFeed sells shares to Byron Allen affiliate for $5.8 million
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings